Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Methsuximide may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Methsuximide may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Methsuximide. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Methsuximide. |
| Buprenorphine | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Hydrocodone | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Methsuximide can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Methsuximide may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Mirtazapine | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Orphenadrine | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Pramipexole | Methsuximide may increase the sedative activities of Pramipexole. |
| Ropinirole | Methsuximide may increase the sedative activities of Ropinirole. |
| Rotigotine | Methsuximide may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide. |
| Sodium oxybate | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Thalidomide | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Dabrafenib | The serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib. |
| Luliconazole | The serum concentration of Methsuximide can be increased when it is combined with Luliconazole. |
| Mefloquine | The therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Methsuximide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Methsuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Cimetidine | The serum concentration of Methsuximide can be increased when it is combined with Cimetidine. |
| Clopidogrel | The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Methsuximide. |
| Efavirenz | The serum concentration of Methsuximide can be decreased when it is combined with Efavirenz. |
| Melatonin | The therapeutic efficacy of Methsuximide can be decreased when used in combination with Melatonin. |
| Nafcillin | The therapeutic efficacy of Methsuximide can be decreased when used in combination with Nafcillin. |
| Nitroprusside | Methsuximide may increase the hypotensive activities of Nitroprusside. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide. |
| Dantrolene | The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Methsuximide. |
| Lithium citrate | The risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium citrate. |
| Lithium carbonate | The risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium carbonate. |
| Lithium hydroxide | The risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium hydroxide. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Methsuximide. |
| Boceprevir | The serum concentration of Methsuximide can be increased when it is combined with Boceprevir. |
| Ethanol | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
| Duloxetine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Methsuximide is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Methsuximide is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Methsuximide is combined with Alaproclate. |
| Escitalopram | The risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram. |
| Lumacaftor | The serum concentration of Methsuximide can be decreased when it is combined with Lumacaftor. |
| Mexiletine | Mexiletine may increase the arrhythmogenic activities of Methsuximide. |
| Tocainide | Tocainide may increase the arrhythmogenic activities of Methsuximide. |
| Aprindine | Aprindine may increase the arrhythmogenic activities of Methsuximide. |
| Carteolol | Methsuximide may increase the arrhythmogenic activities of Carteolol. |
| Metipranolol | Methsuximide may increase the arrhythmogenic activities of Metipranolol. |
| Xylometazoline | Methsuximide may increase the arrhythmogenic activities of Xylometazoline. |
| Sparteine | Methsuximide may increase the arrhythmogenic activities of Sparteine. |
| Fasudil | Methsuximide may increase the arrhythmogenic activities of Fasudil. |
| Spiradoline | Methsuximide may increase the arrhythmogenic activities of Spiradoline. |
| Tiracizine | Methsuximide may increase the arrhythmogenic activities of Tiracizine. |
| Ethacizine | Methsuximide may increase the arrhythmogenic activities of Ethacizine. |
| Hydroquinine | Methsuximide may increase the arrhythmogenic activities of Hydroquinine. |
| Bioallethrin | Methsuximide may increase the arrhythmogenic activities of Bioallethrin. |
| Fosfructose | Methsuximide may increase the arrhythmogenic activities of Fosfructose. |
| Hydroquinidine | Methsuximide may increase the arrhythmogenic activities of Hydroquinidine. |
| SOR-C13 | Methsuximide may increase the arrhythmogenic activities of SOR-C13. |
| Digoxin | Digoxin may increase the arrhythmogenic activities of Methsuximide. |
| Acetyldigitoxin | Acetyldigitoxin may increase the arrhythmogenic activities of Methsuximide. |
| Deslanoside | Deslanoside may increase the arrhythmogenic activities of Methsuximide. |
| Digitoxin | Digitoxin may increase the arrhythmogenic activities of Methsuximide. |
| Cymarin | Methsuximide may increase the arrhythmogenic activities of Cymarin. |
| Metildigoxin | Methsuximide may increase the arrhythmogenic activities of Metildigoxin. |
| Acetyldigoxin | Methsuximide may increase the arrhythmogenic activities of Acetyldigoxin. |
| Hyoscyamine | Hyoscyamine may increase the arrhythmogenic activities of Methsuximide. |
| Nicardipine | Nicardipine may increase the arrhythmogenic activities of Methsuximide. |
| Verapamil | Verapamil may increase the arrhythmogenic activities of Methsuximide. |
| Niguldipine | Methsuximide may increase the arrhythmogenic activities of Niguldipine. |
| Diltiazem | Diltiazem may increase the arrhythmogenic activities of Methsuximide. |
| Nimodipine | Nimodipine may increase the arrhythmogenic activities of Methsuximide. |
| Cinnarizine | Cinnarizine may increase the arrhythmogenic activities of Methsuximide. |
| Atropine | Atropine may increase the arrhythmogenic activities of Methsuximide. |
| Adenosine | Adenosine may increase the arrhythmogenic activities of Methsuximide. |
| Loperamide | Loperamide may increase the arrhythmogenic activities of Methsuximide. |
| Levosimendan | Levosimendan may increase the arrhythmogenic activities of Methsuximide. |
| Nifedipine | Nifedipine may increase the arrhythmogenic activities of Methsuximide. |
| Flecainide | Flecainide may increase the arrhythmogenic activities of Methsuximide. |